Cancer biomarker HER-2/neu in breast cancer in Indian women
In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The...
Saved in:
| Published in | Breast cancer targets and therapy Vol. 3; no. default; pp. 21 - 26 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
New Zealand
Taylor & Francis Ltd
01.01.2011
Dove Press Dove Medical Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.
Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.
Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.
HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available. |
|---|---|
| AbstractList | In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.Materials and methods: Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.Results: Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.Conclusion: HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available. In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors. Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels. Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity. HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available. Rajeev Singhai1, Amit V Patil2, Vinayak W Patil11Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India; 2Department of General Surgery, Government Medical College, Miraj, Maharashtra, IndiaAim and objectives: In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.Materials and methods: Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.Results: Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.Conclusion: HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available.Keywords: breast cancer, serum HER-2/neu receptor assay, hormone receptor, ER, PgR AIM AND OBJECTIVESIn Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors. MATERIALS AND METHODSSerum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels. RESULTSSerum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity. CONCLUSIONHER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available. |
| Author | Singhai, Rajeev Patil, Vinayak W Patil, Amit V |
| AuthorAffiliation | 2 Department of General Surgery, Government Medical College, Miraj, Maharashtra, India 1 Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India |
| AuthorAffiliation_xml | – name: 1 Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India – name: 2 Department of General Surgery, Government Medical College, Miraj, Maharashtra, India |
| Author_xml | – sequence: 1 givenname: Rajeev surname: Singhai fullname: Singhai, Rajeev organization: Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India – sequence: 2 givenname: Amit V surname: Patil fullname: Patil, Amit V organization: Department of General Surgery, Government Medical College, Miraj, Maharashtra, India – sequence: 3 givenname: Vinayak W surname: Patil fullname: Patil, Vinayak W organization: Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24367173$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdUk1r3DAUFCWhSTc59V4MvQSKs9aHLZlCIV3SZiEQSLdnoY_n1Ftb2kp2Sv995Tgbkuiix9No3rxh3qED5x0g9B4X5wQzvvy62mzOf2COC_EGHWPM6xxTzA6e1UfoNMZtMR1eMMbfoiPCaMUxp8fo80o5AyHTre9V-J2qq8vbnCwdjFnrMh1AxSEzMyg11s62ymV_fQ_uBB02qotw-ngv0M9vl5vVVX598329urjODeN0yC2mrAGuBWeMqaJqbMOs5tZgVdaGCQ2YlUrQQhBrDBQlIaRquAZDrKhsSRdoPfNar7ZyF9qk9J_0qpUPDR_upApDazqQCvMGV4TykgtGlKlLbXRta9XwUmsqEteXmWs36h6sATcE1b0gffni2l_yzt9LKtiDZQu03Iu5h12AGF8p2neN72Ul-PTj7HFk8H9GiIPs22ig65QDP0aJWV1wUqelE_TjK-jWj8Elc2UyBddVVdPJj08zygQfY4DmSQEu5JQKOaVCzqlI6A_PN37C7jNA_wPOr7Nb |
| ContentType | Journal Article |
| Copyright | 2011. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2011 Singhai et al, publisher and licensee Dove Medical Press Ltd 2011 |
| Copyright_xml | – notice: 2011. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2011 Singhai et al, publisher and licensee Dove Medical Press Ltd 2011 |
| DBID | NPM AAYXX CITATION 3V. 7X7 7XB 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K9. LK8 M0S M2O M7P MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.2147/BCTT.S17108 |
| DatabaseName | PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Research Library (ProQuest Database) Biological Science Database Research Library (Corporate) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Research Library ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1179-1314 |
| EndPage | 26 |
| ExternalDocumentID | oai_doaj_org_article_a17f1623757842ac95bcb9d9af75bb38 oai_dovepress_com_6877 10_2147_BCTT_S17108 24367173 |
| Genre | Retracted Publication Journal Article Correction/Retraction |
| GroupedDBID | --- 0YH 53G 5VS 7X7 8FE 8FH 8FI 8FJ 8G5 ABUWG ADBBV AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C1A CCPQU DIK DWQXO EBD FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HMCUK HYE IAO ICW IHR IHW IPNFZ ITC KQ8 LK8 M2O M7P M~E NPM OK1 P2P P6G PIMPY PQQKQ PROAC RIG RNS RPM TR2 TUS UKHRP VDV AAYXX CITATION 3V. 7XB 8FK K9. MBDVC PQEST PQUKI PRINS Q9U 7X8 TDBHL - ADACO AGCAB BBAFP 5PM |
| ID | FETCH-LOGICAL-c473t-d134fe7b87444a06fdf4db7dc1a59c48be145a83082dcce052226f7bec2d86d53 |
| IEDL.DBID | RPM |
| ISSN | 1179-1314 |
| IngestDate | Tue Oct 22 14:57:59 EDT 2024 Tue Sep 17 21:03:40 EDT 2024 Mon Jan 18 10:57:37 EST 2021 Fri Oct 25 02:34:44 EDT 2024 Thu Oct 10 18:31:49 EDT 2024 Thu Sep 26 15:51:24 EDT 2024 Sat Sep 28 08:04:50 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | default |
| Keywords | breast cancer PgR hormone receptor serum HER-2/neu receptor assay ER |
| Language | English |
| License | This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c473t-d134fe7b87444a06fdf4db7dc1a59c48be145a83082dcce052226f7bec2d86d53 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Correction/Retraction-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | https://doaj.org/article/a17f1623757842ac95bcb9d9af75bb38 |
| PMID | 24367173 |
| PQID | 2221966935 |
| PQPubID | 3933197 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a17f1623757842ac95bcb9d9af75bb38 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3846717 dovepress_primary_oai_dovepress_com_6877 proquest_miscellaneous_1490729226 proquest_journals_2221966935 crossref_primary_10_2147_BCTT_S17108 pubmed_primary_24367173 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-01-01 |
| PublicationDateYYYYMMDD | 2011-01-01 |
| PublicationDate_xml | – month: 01 year: 2011 text: 2011-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New Zealand |
| PublicationPlace_xml | – name: New Zealand – name: Macclesfield |
| PublicationTitle | Breast cancer targets and therapy |
| PublicationTitleAlternate | Breast Cancer (Dove Med Press) |
| PublicationYear | 2011 |
| Publisher | Taylor & Francis Ltd Dove Press Dove Medical Press |
| Publisher_xml | – name: Taylor & Francis Ltd – name: Dove Press – name: Dove Medical Press |
| References | 14500583 - Clin Chem. 2003 Oct;49(10):1579-98 15865102 - Anticancer Res. 2005 Mar-Apr;25(2B):1433-40 10873087 - Clin Cancer Res. 2000 Jun;6(6):2356-62 16777917 - Clin Chem. 2006 Aug;52(8):1510-5 1967929 - Arch Pathol Lab Med. 1990 Feb;114(2):160-3 10561337 - J Clin Oncol. 1999 Sep;17(9):2639-48 2903446 - N Engl J Med. 1988 Nov 10;319(19):1239-45 12743150 - J Clin Oncol. 2003 May 15;21(10):1967-72 15952182 - Cancer. 2005 Jul 15;104(2):257-63 8538628 - Mutat Res. 1995 Dec;333(1-2):203-8 7579490 - Breast Cancer Res Treat. 1995 Jun;34(3):253-63 11248153 - N Engl J Med. 2001 Mar 15;344(11):783-92 15163844 - Oncologist. 2004;9 Suppl 3:20-6 8001919 - Hum Pathol. 1994 Dec;25(12):1264-8 15245613 - Clin Breast Cancer. 2004 Jun;5(2):105-16 7496836 - Ann Surg Oncol. 1995 Sep;2(5):416-23 11180765 - Breast Cancer. 2001;8(1):45-51 11821453 - J Clin Oncol. 2002 Feb 1;20(3):719-26 3289120 - Science. 1988 Jun 24;240(4860):1795-8 7849090 - Crit Rev Oncog. 1994;5(2-3):313-29 16894399 - Drugs Today (Barc). 2006 Jul;42(7):441-53 24367192 - Breast Cancer (Dove Med Press). 2012;4:33 2999974 - Science. 1985 Dec 6;230(4730):1132-9 2893663 - Cancer Res. 1988 Mar 1;48(5):1238-43 17686164 - BMC Cancer. 2007 Aug 08;7:153 3798106 - Science. 1987 Jan 9;235(4785):177-82 17928597 - N Engl J Med. 2007 Oct 11;357(15):1496-506 15194824 - Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8 15637130 - Clin Chem. 2005 Mar;51(3):494-503 |
| References_xml | |
| SSID | ssj0000070447 |
| Score | 1.851234 |
| SecondaryResourceType | retracted_publication |
| Snippet | In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a... AIM AND OBJECTIVESIn Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be... Rajeev Singhai1, Amit V Patil2, Vinayak W Patil11Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India; 2Department... |
| SourceID | doaj pubmedcentral dovepress proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 21 |
| SubjectTerms | breast cancer hormone receptor Original Research PgR serum HER-2/neu receptor assay |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwEB0hDoUeqkJpmxZQKnHgkm4cO3asnsoKtCDRQ1kkbpa_onLJomW3v78zcXa1iyr1Uikn20qceXbmTTx-BjhDH1g5WnAvddSFiNwX6AUpR8x7GbREPkf7nW9_yMm9uHmoHzaO-qKcsCQPnAw3sky1DH006a6LynpdO-900LZVtXM8bfMt9UYwlYivKoUYTlbRBeNMpM15dCzP6GI8nX69Y-hcmy131Kv2v4a9MPud0lD_RjtfZk9uuKOrt_Bm4JH599T_A9iJ3SG8uh1Wyt_BtzHBOc9pez1l4MzzyeXPohp1cZk_drmjXPRF7lMjLLjuaKDkvSDDEdxfXU7Hk2I4KKHwQvFFERgXbVSOpOyFLWUbWhGcCp7ZWnvRuMhEbRtSpgnexxI5VyVbhfBVoZGh5u9ht5t18SPksUZ-UVY-thK5hmUuas8cpyiytq0vMzhb2cs8JT0Mg3EEmdWQWU0yawYXZMt1ExKx7gsQWjNAa_4FbQbnayRe3GlVirPSyEapDI5XQJlhEj4bfEv8vkgcehl8WVfj9KE1EdvF2fIZIx9N2ulojww-JFzXj6oEl5SkkIHaQnyrL9s13eOvXqKbE61j6tP_MMNn2E8_suk6ht3FfBlPkAkt3Gk_6P8AbAAE8Q priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (Proquest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB5RkNpyqPoC0lIUJA69pBsnjh2rh6qsQEslONBF2pvlV1ouCd0Hv5-ZJBu6qKqUk2051szY83k8_gxwgj4ws3TgnqqgEh5yl6AXpBwx54RXAvEc3Xe-vBKTG_5jVsz6gNuiT6tcr4ntQu0bRzHyEfoxNBaB_Xy7-5PQq1F0uto_ofEMdliWCkrpkjM5xFiIy4Zz2V3Lowd5Rqfj6fTLT4ZutdxwRC1f_y688M19l4D6L8D5NG_yL0d0_hpe9Qgy_t6p_A1shfotPL_sz8jfwdcxKXIe08V6yr2Zx5Oz6yQb1WEV39axpSz0Zey6RlhwUZOJxC0Vw3u4OT-bjidJ_0RC4rjMl4lnOa-CtERiz00qKl9xb6V3zBTK8dIGxgtTEieNdy6kiLYyUUlUXOZL4Yt8D7brpg4HEIcCkUWauVAJRBmG2aAcszntHwtTuTSCk7W89F3HhKFxB0Fi1SRW3Yk1glOS5dCE6Kvbgmb-S_ezQRsmK4bAi8j0eWacKqyzyitTycLaHDv5PGjiSU_rUrQNLUopIzhcK0r302-hH40lguOhGicOnYaYOjSrBe55FLGmozwi2O_0Ovwq47mg9IQI5IbGN8ayWVPf_m7JuXMCdEx--P-wPsLLLjhN3yFsL-er8AnRzdIetSb8AKKT-l8 priority: 102 providerName: ProQuest |
| Title | Cancer biomarker HER-2/neu in breast cancer in Indian women |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24367173 https://www.proquest.com/docview/2221966935 https://search.proquest.com/docview/1490729226 http://www.dovepress.com/getfile.php?fileID=9447 https://pubmed.ncbi.nlm.nih.gov/PMC3846717 https://doaj.org/article/a17f1623757842ac95bcb9d9af75bb38 |
| Volume | 3 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aDrbuoeyz89YGD_qwF8eWJVkxe1pCumyQUroU8masD2-B1Slpsr9_d5YdmtKngvGDPmz57uT7STr9BHCGPjDVtOCe5C6PhOMmQi9IMWLGZDbPEM_RfufpRTa5Fj_ncr4HstsL0wTtG73o139v-vXiTxNbeXtj4i5OLL6cjjg5TabifdhHA703RPeYVyVCKL8Xj07hiYej2az_i6EvpdP5UsGpMt9xRA1f_0t4YZf_fADqY4DzYdzkPUd0_gqOWgQZfvMtfQ17rn4Dz6ftGvlb-DoiRa5C2lhPsTercDK-itK4dptwUYeaotDXofGFMOFHTSYSNlQM7-D6fDwbTaL2iITICMXXkWVcVE5pIrEXZZJVthJWK2tYKXMjBtoxIcsBcdJYY1yCaCvNKoWKS-0gs5K_h4N6WbsPEDqJyCJJjasyRBkl0y43THMaP8qyMkkAZ528ilvPhFHgCIIkXJCECy_hAIYky20Roq9uEpar30WrxKJkqmIIvIhMX6SlyaU2Ord5WSmpNceHfNlq4sGTulTsj0U2UCqAk05RRdv97gr8SvyzZGh0AXzeZmPHodWQsnbLzR2OeXJiTUd5BHDs9bp9VWcjAagdje-0ZTcHbbUh525t8-OTa36CQz9vTdcJHKxXG3eKwGete2juc9WDZ8PxxeVVr5k-wPv3Oes1XeA_-gsHzQ |
| link.rule.ids | 230,315,730,783,787,867,888,2109,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806,74073,74630 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BK9FyQLwbKBCkHriEzcOxY3Go2NVWW-iuUNlKvVnxI9BLUvbR39-ZxBu6FULKybYca2bs-TwefwY4Qh-Yajpwj6WTEXOZidALUo6YMdxKjniO7jtPZ3xywb5d5pc-4Lb0aZWbNbFdqG1jKEY-QD-GxsKxn-PrPxG9GkWnq_4JjYewS1RVuPnaHY5nP877KAux2TAmuot59CTPYDiazz__TNCxFluuqGXsfwx7trnpUlD_BTnvZ07ecUUnT-GJx5Dh107pz-CBq5_Do6k_JX8BX0akykVIV-sp-2YRTsbnUTqo3Tq8qkNNeeir0HSNsOC0JiMJWzKGl3BxMp6PJpF_JCEyTGSryCYZq5zQRGPPyphXtmJWC2uSMpeGFdolLC8LYqWxxrgY8VbKK4GqS23BbZ69gp26qd0BhC5HbBGnxlUccUaZaCdNojPaQeZlZeIAjjbyUtcdF4bCPQSJVZFYVSfWAIYky74JEVi3Bc3il_LzQZWJqBKEXkSnz9LSyFwbLa0sK5FrnWEnn3pN3OtpU4rWoXghRACHG0UpPwGX6q-5BPCxr8apQ-chZe2a9RJ3PZJ401EeAbzu9Nr_KmUZpwSFAMSWxrfGsl1TX_1u6bkzgnSJePP_YX2Avcl8eqbOTmff38J-F6qm7xB2Vou1e4dYZ6Xfe4O-BdDG_rU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVipwQLxKAwWC1AOXsHk4diIOiF12tQW6qspW6s3yK9BL0u6D389M4g1shZBysiPHmhlnPtufPwMcYw5MNW24x6UrI-YyE2EWJI6YMdyWHPEcnXc-nfPZBftymV96_tPK0yq3_8T2R20bQ2vkQ8xjGCwc2xlWnhZx9nn68fomohukaKfVX6dxF_YE41k8gL3RZH523q-4kLINY6I7pEfX8wxH48Xi_fcEk2yxk5Za9f4HcM82vzo66r_g520W5V9pafoIHno8GX7qAuAx3HH1E9g_9TvmT-HDmNy6DOmYPTFxluFsch6lw9ptwqs61MRJX4emewkLTmoKmLAVZngGF9PJYjyL_IUJkWEiW0c2yVjlhCZJe6ZiXtmKWS2sSVReGlZol7BcFaRQY41xMWKvlFcC3Zjagts8O4BB3dTuEEKXI86IU-MqjphDJdqVJtEZzSZzVZk4gOOtveR1p4shcT5BZpVkVtmZNYAR2bJ_hcSs24Jm-UP6sSFVIqoEYRhJ67NUmTLXRpe2VJXItc6wkXe9J261tC3FSJG8ECKAo62jpB-MK_kndAJ421fjMKK9EVW7ZrPCGVBJGupojwCed37tP5WyjBNZIQCx4_GdvuzW1Fc_W6nujOBdIl78v1tvYB9jWX47mX99Cfe7VWt6jmCwXm7cK4Q9a_3ax_NvkYgC8g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cancer+biomarker+HER-2%2Fneu+in+breast+cancer+in+Indian+women&rft.jtitle=Breast+cancer+targets+and+therapy&rft.au=Singhai+R&rft.au=Patil+VW&rft.au=Patil+AV&rft.date=2011-01-01&rft.pub=Dove+Medical+Press&rft.issn=1179-1314&rft.eissn=1179-1314&rft.volume=2011&rft.issue=default&rft.spage=21&rft.epage=26&rft_id=info:doi/10.2147%2FBCTT.S17108&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_a17f1623757842ac95bcb9d9af75bb38 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1179-1314&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1179-1314&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1179-1314&client=summon |